A phase 2, 24-week, randomized, placebo-controlled, double-blind study examining the efficacy and safety of an anti-interleukin-12 and -23 monoclonal antibody in patients with relapsing–remitting or secondary progressive multiple sclerosis

Background: Interleukins 12 and 23 (IL-12/23) have been implicated in multiple sclerosis (MS) pathogenesis. This study assessed the efficacy and safety of ABT-874, a monoclonal anti-IL-12/23 antibody, in active relapsing–remitting MS (RRMS) or secondary progressive MS (SPMS). Methods: In this 24-wee...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Multiple sclerosis 2011-02, Vol.17 (2), p.181-191
Hauptverfasser:	Vollmer, Timothy L, Wynn, Daniel R, Alam, M Shamsul, Valdes, Joaquin
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use Canada Disability Evaluation Disease Progression Double-Blind Method Europe Female Humans Interleukin-12 - immunology Interleukin-23 - immunology Magnetic Resonance Imaging Male Middle Aged Multiple Sclerosis, Chronic Progressive - diagnosis Multiple Sclerosis, Chronic Progressive - drug therapy Multiple Sclerosis, Chronic Progressive - immunology Multiple Sclerosis, Relapsing-Remitting - diagnosis Multiple Sclerosis, Relapsing-Remitting - drug therapy Multiple Sclerosis, Relapsing-Remitting - immunology Placebo Effect Recurrence Time Factors Treatment Outcome United States
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!